SHANGHAI, June 24, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP…
News provided by PR Newswire.
